These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 25959702)

  • 21. Polymorphisms associated with resistance to protease inhibitors in naïve patients infected with hepatitis C virus genotype 1 in Argentina: Low prevalence of Q80K.
    Martínez AP; Culasso ACA; Pérez PS; Romano V; Campos RH; Ridruejo E; García G; Di Lello FA
    Virus Res; 2017 Aug; 240():140-146. PubMed ID: 28837817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protease inhibitor resistance mutations in untreated Brazilian patients infected with HCV: novel insights about targeted genotyping approaches.
    de Carvalho IM; Alves R; de Souza PA; da Silva EF; Mazo D; Carrilho FJ; Queiroz AT; Pessoa MG
    J Med Virol; 2014 Oct; 86(10):1714-21. PubMed ID: 25042789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients.
    Trimoulet P; Belzunce C; Faure M; Wittkop L; Reigadas S; Dupon M; Ragnaud JM; Fleury H; Neau D
    HIV Med; 2011 Sep; 12(8):506-9. PubMed ID: 21410862
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extent of HCV NS3 protease variability and resistance-associated mutations assessed by next generation sequencing in HCV monoinfected and HIV/HCV coinfected patients.
    Bartolini B; Giombini E; Zaccaro P; Selleri M; Rozera G; Abbate I; Comandini UV; Ippolito G; Solmone M; Capobianchi MR
    Virus Res; 2013 Nov; 177(2):205-8. PubMed ID: 23954579
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients.
    Paolucci S; Fiorina L; Piralla A; Gulminetti R; Novati S; Barbarini G; Sacchi P; Gatti M; Dossena L; Baldanti F
    Virol J; 2012 Oct; 9():245. PubMed ID: 23095680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In Vitro Activity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed Mutants.
    Verbinnen T; Fevery B; Vijgen L; Jacobs T; De Meyer S; Lenz O
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7548-57. PubMed ID: 26392483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-naïve subjects.
    Vidal LL; Soares MA; Santos AF
    J Viral Hepat; 2016 Nov; 23(11):840-849. PubMed ID: 26775769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Determination of the naturally occurring Q80K mutation in the HCV NS3 protease gene].
    Kutová R; Plíšková L; Štěpánová V; Plíšek S; Machač J
    Klin Mikrobiol Infekc Lek; 2015 Dec; 21(4):126-9. PubMed ID: 26886497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations.
    Aloia AL; Eyre NS; Black S; Bent SJ; Gaeguta A; Guo Z; Narayana SK; Chase R; Locarnini S; Carr JM; Howe JA; Beard MR
    Antivir Ther; 2015; 20(3):271-80. PubMed ID: 25222708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis C virus genotypes in Tirana, Albania.
    Haldeda M; Baume J; Tamalet C; Bizhga M; Colson P
    Int J Infect Dis; 2014 Jan; 18():90-3. PubMed ID: 24169401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of robust in vitro serine protease assay based on recombinant Pakistani HCV NS3-4A protease.
    Fatima K; Tahir M; Qadri I
    Virus Res; 2011 Sep; 160(1-2):230-7. PubMed ID: 21756947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region.
    Sarrazin C; Lathouwers E; Peeters M; Daems B; Buelens A; Witek J; Wyckmans Y; Fevery B; Verbinnen T; Ghys A; Schlag M; Baldini A; De Meyer S; Lenz O
    Antiviral Res; 2015 Apr; 116():10-6. PubMed ID: 25614456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Similarities between Human Immunodeficiency Virus Type 1 and Hepatitis C Virus Genetic and Phenotypic Protease Quasispecies Diversity.
    Martinez MA; Nevot M; Jordan-Paiz A; Franco S
    J Virol; 2015 Oct; 89(19):9758-64. PubMed ID: 26178979
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natural variability of NS3 protease in patients infected with genotype 4 hepatitis C virus (HCV): implications for antiviral treatment using specifically targeted antiviral therapy for HCV.
    Akhavan S; Schnuriger A; Lebray P; Benhamou Y; Poynard T; Thibault V
    J Infect Dis; 2009 Aug; 200(4):524-7. PubMed ID: 19604114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic background for development of resistance mutations within the HCV NS3 protease-helicase in direct acting antiviral naive patients.
    Grammatikos G; Jabara CB; Ahmad MQ; Herrmann E; Zeuzem S; Welsch C
    Antivir Ther; 2014; 19(5):455-61. PubMed ID: 24457994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natural prevalence of HCV minority variants that are highly resistant to NS3/4A protease inhibitors.
    Franco S; Bellido R; Aparicio E; Cañete N; García-Retortillo M; Solà R; Tural C; Clotet B; Paredes R; Martínez MA
    J Viral Hepat; 2011 Oct; 18(10):e578-82. PubMed ID: 21914079
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natural prevalence of hepatitis C virus (HCV) variants resistant to protease and polymerase inhibitors in patients infected with HCV genotype 1 in Tunisia.
    Aissa Larousse J; Trimoulet P; Recordon-Pinson P; Papuchon J; Azzouz MM; Ben Mami N; Cheikh I; Triki H; Fleury H
    J Med Virol; 2014 Aug; 86(8):1350-9. PubMed ID: 24760718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predominance of hepatitis C virus Q80K among NS3 baseline-resistance-associated amino acid variants in direct-antiviral-agent-naïve patients with chronic hepatitis: single-centre experience.
    Ruggiero T; Proietti A; Boglione L; Milia MG; Allice T; Burdino E; Orofino G; Bonora S; Di Perri G; Ghisetti V
    Arch Virol; 2015 Nov; 160(11):2881-5. PubMed ID: 26249823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of highly active antiretroviral therapy on hepatitis C virus protease quasispecies diversity in HIV co-infected patients.
    Winters MA; Chary A; Eison R; Asmuth D; Holodniy M
    J Med Virol; 2010 May; 82(5):791-8. PubMed ID: 20336744
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The hepatitis C virus nonstructural protein 3 Q80K polymorphism is frequently detected and transmitted among HIV-infected MSM in the Netherlands.
    Newsum AM; Ho CK; Lieveld FI; van de Laar TJ; Koekkoek SM; Rebers SP; van der Meer JT; Wensing AM; Boland GJ; Arends JE; van Erpecum KJ; Prins M; Molenkamp R; Schinkel J
    AIDS; 2017 Jan; 31(1):105-112. PubMed ID: 27898592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.